Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies

NCT07662681 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: camrelizumab with famitinib

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University